Skip to content

Pulmonx Corporation LUNG Fair Value Measurement Disclosure

Fair Value Measurement Disclosure at other companies

Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-43.7%
Enterprise value$50.17M-39.2%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's fair value measurement disclosure.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's fair value measurement disclosure?
Pulmonx Corporation (LUNG) reported fair value measurement disclosure of $277K in Q1 2026.
What does fair value measurement disclosure mean?
This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.